Submitted for Publication: December 9, 2012; final revision received July 11, 2013; accepted July 18, 2013.
Published Online: December 4, 2013. doi:10.1001/jamapsychiatry.2013.3469.
Study concept and design: Baker, Buckner, Öngür.
Acquisition of data: Baker, Holmes, Masters, Buckner, Öngür.
Analysis and interpretation of data: Baker, Holmes, Yeo, Krienen, Buckner, Öngür.
Drafting of the manuscript: Baker, Holmes, Masters, Yeo, Öngür.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Baker, Holmes, Yeo, Krienen, Buckner.
Obtained funding: Baker, Buckner, Öngür.
Administrative, technical, and material support: Holmes, Masters, Yeo, Krienen, Buckner, Öngür.
Study supervision: Buckner, Öngür.
Conflict of Interest Disclosures: Dr Buckner is a paid consultant for Pfizer, Inc and Johnson & Johnson. Dr Öngür serves on the advisory board for Lilly.
Funding/Support: This study was funded by grants 1K23MH079982-01A1, 5R01MH094594 from the National Institute of Mental Health (Dr Öngür), the Clinical Investigator Training Fellowship from Harvard/MIT (Dr Öngür), and the Taplin Family Foundation. Dr Baker is supported by a Dupont-Warren Fellowship (HMS), the APA-Pfizer MD/PhD Fellowship, and the Maria Lorenz Pope Fellowship. Dr Holmes is supported by K01MH099232 from the National Institute of Mental Health.
Role of the Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Marisa Hollinshead, BA, Julie McCarthy, BA, and Alissa Cooper, BA, assisted with participant recruitment, clinical assessment, and scanning. Subjects were provided monetary compensation for their participation.